COMP <GO>
MAZE vs REPL // EV/EBITDA & P/E VALUATION
Maze Therapeutics Inc. (NASDAQ) VS. Replimune Group Inc. (NASDAQ) • 15-METRIC TALLY: MAZE 2
— REPL 2
■ METRIC PARITY
LAST: $31.93 (+0.63%) • MKT CAP: $1.77B
valuation
—
LAST: $17.39 (+8.28%) • MKT CAP: $1.65B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MAZE VS. REPL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MAZE | REPL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.36% | -17.01% | +10.65 | MAZE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | REPL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 75.1 | -11.86 | REPL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.77B | $1.65B | $125.1M | MAZE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MAZE REV | REPL REV | MAZE GROSS % | REPL GROSS % | MAZE FCF | REPL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$112.7M | -$280.3M |
| FY 2024 | $167.5M | $0 | — | — | $74.8M | -$192.3M |
| FY 2023 | — | $0 | — | — | — | -$185.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MAZE // BETA —
REPL // BETA —